662 related articles for article (PubMed ID: 33426042)
1. Understanding the molecular-pharmaceutical basis of sartan recalls focusing on valsartan.
Ray A; Atal S; Sadasivam B
Glob Cardiol Sci Pract; 2020 Nov; 2020(2):e202025. PubMed ID: 33426042
[TBL] [Abstract][Full Text] [Related]
2. Investigation of Carcinogenic Impurities of N-Nitrosamines in Sartan Pharmaceutical Products Marketed in Brazil: Development and Validation of Method Based on High-Performance Liquid Chromatography-Tandem Mass Spectrometry.
Monteiro MA; de Lima PC; Novotny TS; Santana DS; Lima MED; Dantas ASCL; Ferreira LODS; de Souza MN; Maranho RLDN; Ochs SM
J Pharm Sci; 2023 May; 112(5):1305-1314. PubMed ID: 36657719
[TBL] [Abstract][Full Text] [Related]
3. Determination of N-nitrosodimethylamine and N-nitrosomethylethylamine in drug substances and products of sartans, metformin and ranitidine by precipitation and solid phase extraction and gas chromatography-tandem mass spectrometry.
Lim HH; Oh YS; Shin HS
J Pharm Biomed Anal; 2020 Sep; 189():113460. PubMed ID: 32663759
[TBL] [Abstract][Full Text] [Related]
4. Lesson Learnt from Recall of Valsartan and Other Angiotensin II Receptor Blocker Drugs Containing NDMA and NDEA Impurities.
Charoo NA; Ali AA; Buha SK; Rahman Z
AAPS PharmSciTech; 2019 Apr; 20(5):166. PubMed ID: 30989447
[TBL] [Abstract][Full Text] [Related]
5. Neoplasm Reports in Food and Drug Administration Adverse Event Reporting System Following Angiotensin Receptor Blocker Recalls.
Cohen Sedgh R; Moon J; Jackevicius CA
Circ Cardiovasc Qual Outcomes; 2021 Aug; 14(8):e007476. PubMed ID: 34380327
[TBL] [Abstract][Full Text] [Related]
6. Nitrosamine Impurities in Pharmaceuticals: An Empirical Review of their Detection, Mechanisms, and Regulatory Approaches.
Bhirud D; Agrawal G; Shah H; Patel A; Palkar MB; Bhattacharya S; Prajapati BG
Curr Top Med Chem; 2024; 24(6):503-522. PubMed ID: 38321910
[TBL] [Abstract][Full Text] [Related]
7. Rapid Quantitation of Four Nitrosamine Impurities in Angiotensin Receptor Blocker Drug Substances.
Zhang J; Selaya SD; Shakleya D; Mohammad A; Faustino PJ
J Pharm Sci; 2023 May; 112(5):1246-1254. PubMed ID: 36509171
[TBL] [Abstract][Full Text] [Related]
8. The contamination of valsartan and other sartans, Part 2: Untargeted screening reveals contamination with amides additionally to known nitrosamine impurities.
Scherf-Clavel O; Kinzig M; Besa A; Schreiber A; Bidmon C; Abdel-Tawab M; Wohlfart J; Sörgel F; Holzgrabe U
J Pharm Biomed Anal; 2019 Aug; 172():278-284. PubMed ID: 31078064
[TBL] [Abstract][Full Text] [Related]
9. Metformin drugs under simulated gastric conditions can generate high nitrite-dependent levels of N-nitrosodimethylamine.
Georgescu GC; Cretu-Stancu M; Bucur O
Sci Rep; 2024 Jun; 14(1):13910. PubMed ID: 38886399
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous detection of nitrosamines and other sartan-related impurities in active pharmaceutical ingredients by supercritical fluid chromatography.
Schmidtsdorff S; Schmidt AH
J Pharm Biomed Anal; 2019 Sep; 174():151-160. PubMed ID: 31174128
[TBL] [Abstract][Full Text] [Related]
11. An update on the current status and prospects of nitrosation pathways and possible root causes of nitrosamine formation in various pharmaceuticals.
Wichitnithad W; Nantaphol S; Noppakhunsomboon K; Rojsitthisak P
Saudi Pharm J; 2023 Feb; 31(2):295-311. PubMed ID: 36942272
[TBL] [Abstract][Full Text] [Related]
12. The contamination of valsartan and other sartans, part 1: New findings.
Sörgel F; Kinzig M; Abdel-Tawab M; Bidmon C; Schreiber A; Ermel S; Wohlfart J; Besa A; Scherf-Clavel O; Holzgrabe U
J Pharm Biomed Anal; 2019 Aug; 172():395-405. PubMed ID: 31122801
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension.
Israili ZH
J Hum Hypertens; 2000 Apr; 14 Suppl 1():S73-86. PubMed ID: 10854085
[TBL] [Abstract][Full Text] [Related]
14. Critical Analysis of Drug Product Recalls due to Nitrosamine Impurities.
Bharate SS
J Med Chem; 2021 Mar; 64(6):2923-2936. PubMed ID: 33706513
[TBL] [Abstract][Full Text] [Related]
15. The plague of unexpected drug recalls and the pandemic of falsified medications in cardiovascular medicine as a threat to patient safety and global public health: A brief review.
Świeczkowski D; Zdanowski S; Merks P; Szarpak Ł; Vaillancourt R; Jaguszewski MJ
Cardiol J; 2022; 29(1):133-139. PubMed ID: 33346374
[TBL] [Abstract][Full Text] [Related]
16. NDMA impurity in valsartan and other pharmaceutical products: Analytical methods for the determination of N-nitrosamines.
Parr MK; Joseph JF
J Pharm Biomed Anal; 2019 Feb; 164():536-549. PubMed ID: 30458387
[TBL] [Abstract][Full Text] [Related]
17. Cost-effective, green HPLC determination of losartan, valsartan and their nitrosodiethylamine impurity: application to pharmaceutical dosage forms.
Abd El-Hay SS; Elhenawee M; Maged K; Ibrahim AE
R Soc Open Sci; 2022 Jun; 9(6):220250. PubMed ID: 35706671
[TBL] [Abstract][Full Text] [Related]
18. Presence of nitrosamine impurities in medicinal products.
Sedlo I; Kolonić T; Tomić S
Arh Hig Rada Toksikol; 2021 Mar; 72(1):1-5. PubMed ID: 33787187
[TBL] [Abstract][Full Text] [Related]
19. The place of ARBs in heart failure therapy: is aldosterone suppression the key?
Markan U; Pasupuleti S; Pollard CM; Perez A; Aukszi B; Lymperopoulos A
Ther Adv Cardiovasc Dis; 2019; 13():1753944719868134. PubMed ID: 31401939
[TBL] [Abstract][Full Text] [Related]
20. Pharmacists are key in interpreting clinical implications of N-nitrosodimethylamine contamination in medications.
Eads AV
J Am Pharm Assoc (2003); 2020; 60(6):e100-e104. PubMed ID: 32741598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
